SCHEMBL3592730

SCHEMBL3592730

CCCCCCCCCC[CH]c1ccccc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.44
CA2 P00918 4/20 0.44
CA9 Q16790 4/20 0.44
MAPT P10636 3/20 0.42
F7 P08709 3/20 0.42
F3 P13726 3/20 0.42
MMP2 P08253 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALOX15 P16050 1/20 0.42
ECE1 P42892 1/20 0.42
SGMS1 Q86VZ5 1/20 0.42
SGMS2 Q8NHU3 1/20 0.42
MUS81 Q96NY9 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3587145 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL3597535 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL10516475 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL3584638 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL4469886 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL3600856 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL3602229 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL3601328 1.00 CA12 (0.44) CA12CA2CA9MAPTF7
SCHEMBL743669 0.98 MAPT (0.43) CA12CA2CA9MAPTF7
SCHEMBL9663811 0.92 MAPT (0.44) CA12CA2CA9MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741242-B2 Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
EP-1537913-B1 PALLADIUM CATALYST COMPOSITION WAKO PURE CHEMICAL INDUSTIES L (JP) 2009-07-01 EP disclosed
US-20060019822-A1 Palladium catalyst composition JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2006-01-26 US disclosed
EP-1537913-A1 PALLADIUM CATALYST COMPOSITION Wako Pure Chemical Industies, Ltd. (JP) 2005-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019822-A1 Palladium catalyst composition ODC1, NUDC, ADH1C CA12 508/4885CA2 2021/4885CA9 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.